Pharmacological Inhibition of Feline Immunodeficiency Virus (FIV)
Open Access
Abstract
Feline immunodeficiency virus (FIV) is a member of the retroviridae family of viruses and causes an acquired immunodeficiency syndrome (AIDS) in domestic and non-domestic cats worldwide. Genome organization of FIV and clinical characteristics of the disease caused by the virus are similar to those of human immunodeficiency virus (HIV). Both viruses infect T lymphocytes, monocytes and macrophages, and their replication cycle in infected cells is analogous. Due to marked similarity in genomic organization, virus structure, virus replication and disease pathogenesis of FIV and HIV, infection of cats with FIV is a useful tool to study and develop novel drugs and vaccines for HIV. Anti-retroviral drugs studied extensively in HIV infection have targeted different steps of the virus replication cycle: (1) inhibition of virus entry into susceptible cells at the level of attachment to host cell surface receptors and co-receptors; (2) inhibition of fusion of the virus membrane with the cell membrane; (3) blockade of reverse transcription of viral genomic RNA; (4) interruption of nuclear translocation and viral DNA integration into host genomes; (5) prevention of viral transcript processing and nuclear export; and (6) inhibition of virion assembly and maturation. Despite much success of anti-retroviral therapy slowing disease progression in people, similar therapy has not been thoroughly investigated in cats. In this article we review current pharmacological approaches and novel targets for anti-lentiviral therapy, and critically assess potentially suitable applications against FIV infection in cats.Keywords
This publication has 93 references indexed in Scilit:
- Identification of Amino Acid Residues Important for Heparan Sulfate Proteoglycan Interaction within Variable Region 3 of the Feline Immunodeficiency Virus Surface GlycoproteinJournal of Virology, 2011
- New Approaches for Antiviral Targeting of HIV AssemblyJournal of Molecular Biology, 2011
- Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody IbalizumabJournal of Virology, 2011
- Antiretroviral Treatment 2010: Progress and ControversiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- High-Affinity Glycopolymer Binding to Human DC-SIGN and Disruption of DC-SIGN Interactions with HIV Envelope GlycoproteinJournal of the American Chemical Society, 2010
- Potent Lentiviral Restriction by a Synthetic Feline TRIM5 Cyclophilin A FusionJournal of Virology, 2010
- Identification of broad-based HIV-1 protease inhibitors from combinatorial librariesBiochemical Journal, 2010
- Fragment‐Based Screen against HIV ProteaseChemical Biology & Drug Design, 2010
- Inhibition of Envelope-Mediated CD4+-T-Cell Depletion by Human Immunodeficiency Virus Attachment InhibitorsAntimicrobial Agents and Chemotherapy, 2009
- Mapping the Domains of CD134 as a Functional Receptor for Feline Immunodeficiency VirusJournal of Virology, 2006